
    
      This study is a phase III multi-center, randomized, open-label, parallel control study to
      evaluate the efficacy and safety of recombinant humanized anti-HER2 monoclonal
      antibody-Monomethyl auristatin E (MMAE) conjugate for the treatment of HER2-overexpression
      locally advanced or metastatic gastric cancer. The HER2-overexpression is defined as: the
      HER2 IHC 3+ or 2+, regardless of FISH status.
    
  